Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report

William S. Gilmer, Jackie K. Gollan, Stephen R. Wisniewski, Robert H. Howland, Madhukar H. Trivedi, Sachiko Miyahara, Jenelle Fleck, Michael E. Thase, Jonathan E. Alpert, Andrew A. Nierenberg, Diane Warden, Maurizio Fava, A. John Rush

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: This article aims to identify baseline sociodemographic and clinical characteristics associated with the duration of the index major depressive episode (MDE) and to assess the effect of the current MDE duration on response and remission rates with up to 14 weeks of citalopram. Method: Eligible participants met DSM-IV criteria for nonpsychotic major depressive disorder, scored ≥ 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17), and were not resistant to adequate antidepressant treatment in the current episode. The first patient was enrolled in July 2001 and the last visit for the last patient in follow-up was in March 2006. The evaluable sample (N = 2851) was divided into 4 groups based on the index MDE duration at study entry: acute (≤ 6 months, N = 1324), subchronic (7-23 months, N = 807), chronic (24-41 months, N = 326), and ultrachronic (≥ 42 months, N = 394). These 4 groups were compared in terms of baseline sociodemographic and clinical characteristics and treatment outcomes. Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6. Logistic regression models with adjusted post hoc analyses were used to control for associated baseline characteristics. Response was defined as ≥ 50% reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDSSR-16) scores at exit. Remission was defined as ≤ 7 on the HAM-D-17 or ≤ 5 on the QIDS-SR-16. Results: MDE duration was longer in primary care settings, blacks, Hispanics, single or widowed, unemployed, publicly insured or uninsured, older, and less educated participants and in those with lower income, less recurrence, or greater concurrent general medical or Axis I comorbidities. HAM-D-17 remission rates ranged from 31.0% (acute group) to 24.1% (ultrachronic group). HAM-D-17 remission rates were significantly related to MDE duration (p = .0010), but after adjustments for baseline differences among the 4 groups, remission rates were not different. QIDS-SR-16 response rates were lower for the subacute and chronic groups but not different for the acute and ultrachronic groups after adjustment. Conclusion: Longer MDE duration is associated with socioeconomic disadvantage and greater Axis I and medical comorbidity. Episode duration per se does not significantly affect the likelihood of remission. Trial Registration: clinicaltrials.gov Identifier: NCT00021528.

Original languageEnglish (US)
Pages (from-to)1246-1256
Number of pages11
JournalJournal of Clinical Psychiatry
Volume69
Issue number8
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Citalopram
Major Depressive Disorder
Comorbidity
Logistic Models
Social Adjustment
Widowhood
Hispanic Americans
Diagnostic and Statistical Manual of Mental Disorders
Self Report
Antidepressive Agents
Primary Health Care
Depression
Recurrence
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Gilmer, W. S., Gollan, J. K., Wisniewski, S. R., Howland, R. H., Trivedi, M. H., Miyahara, S., ... Rush, A. J. (2008). Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. Journal of Clinical Psychiatry, 69(8), 1246-1256.

Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. / Gilmer, William S.; Gollan, Jackie K.; Wisniewski, Stephen R.; Howland, Robert H.; Trivedi, Madhukar H.; Miyahara, Sachiko; Fleck, Jenelle; Thase, Michael E.; Alpert, Jonathan E.; Nierenberg, Andrew A.; Warden, Diane; Fava, Maurizio; Rush, A. John.

In: Journal of Clinical Psychiatry, Vol. 69, No. 8, 08.2008, p. 1246-1256.

Research output: Contribution to journalArticle

Gilmer, WS, Gollan, JK, Wisniewski, SR, Howland, RH, Trivedi, MH, Miyahara, S, Fleck, J, Thase, ME, Alpert, JE, Nierenberg, AA, Warden, D, Fava, M & Rush, AJ 2008, 'Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report', Journal of Clinical Psychiatry, vol. 69, no. 8, pp. 1246-1256.
Gilmer WS, Gollan JK, Wisniewski SR, Howland RH, Trivedi MH, Miyahara S et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. Journal of Clinical Psychiatry. 2008 Aug;69(8):1246-1256.
Gilmer, William S. ; Gollan, Jackie K. ; Wisniewski, Stephen R. ; Howland, Robert H. ; Trivedi, Madhukar H. ; Miyahara, Sachiko ; Fleck, Jenelle ; Thase, Michael E. ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Warden, Diane ; Fava, Maurizio ; Rush, A. John. / Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. In: Journal of Clinical Psychiatry. 2008 ; Vol. 69, No. 8. pp. 1246-1256.
@article{8c214e6776b24383ae48b1cd4e61e392,
title = "Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report",
abstract = "Objective: This article aims to identify baseline sociodemographic and clinical characteristics associated with the duration of the index major depressive episode (MDE) and to assess the effect of the current MDE duration on response and remission rates with up to 14 weeks of citalopram. Method: Eligible participants met DSM-IV criteria for nonpsychotic major depressive disorder, scored ≥ 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17), and were not resistant to adequate antidepressant treatment in the current episode. The first patient was enrolled in July 2001 and the last visit for the last patient in follow-up was in March 2006. The evaluable sample (N = 2851) was divided into 4 groups based on the index MDE duration at study entry: acute (≤ 6 months, N = 1324), subchronic (7-23 months, N = 807), chronic (24-41 months, N = 326), and ultrachronic (≥ 42 months, N = 394). These 4 groups were compared in terms of baseline sociodemographic and clinical characteristics and treatment outcomes. Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6. Logistic regression models with adjusted post hoc analyses were used to control for associated baseline characteristics. Response was defined as ≥ 50{\%} reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDSSR-16) scores at exit. Remission was defined as ≤ 7 on the HAM-D-17 or ≤ 5 on the QIDS-SR-16. Results: MDE duration was longer in primary care settings, blacks, Hispanics, single or widowed, unemployed, publicly insured or uninsured, older, and less educated participants and in those with lower income, less recurrence, or greater concurrent general medical or Axis I comorbidities. HAM-D-17 remission rates ranged from 31.0{\%} (acute group) to 24.1{\%} (ultrachronic group). HAM-D-17 remission rates were significantly related to MDE duration (p = .0010), but after adjustments for baseline differences among the 4 groups, remission rates were not different. QIDS-SR-16 response rates were lower for the subacute and chronic groups but not different for the acute and ultrachronic groups after adjustment. Conclusion: Longer MDE duration is associated with socioeconomic disadvantage and greater Axis I and medical comorbidity. Episode duration per se does not significantly affect the likelihood of remission. Trial Registration: clinicaltrials.gov Identifier: NCT00021528.",
author = "Gilmer, {William S.} and Gollan, {Jackie K.} and Wisniewski, {Stephen R.} and Howland, {Robert H.} and Trivedi, {Madhukar H.} and Sachiko Miyahara and Jenelle Fleck and Thase, {Michael E.} and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Diane Warden and Maurizio Fava and Rush, {A. John}",
year = "2008",
month = "8",
language = "English (US)",
volume = "69",
pages = "1246--1256",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report

AU - Gilmer, William S.

AU - Gollan, Jackie K.

AU - Wisniewski, Stephen R.

AU - Howland, Robert H.

AU - Trivedi, Madhukar H.

AU - Miyahara, Sachiko

AU - Fleck, Jenelle

AU - Thase, Michael E.

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Warden, Diane

AU - Fava, Maurizio

AU - Rush, A. John

PY - 2008/8

Y1 - 2008/8

N2 - Objective: This article aims to identify baseline sociodemographic and clinical characteristics associated with the duration of the index major depressive episode (MDE) and to assess the effect of the current MDE duration on response and remission rates with up to 14 weeks of citalopram. Method: Eligible participants met DSM-IV criteria for nonpsychotic major depressive disorder, scored ≥ 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17), and were not resistant to adequate antidepressant treatment in the current episode. The first patient was enrolled in July 2001 and the last visit for the last patient in follow-up was in March 2006. The evaluable sample (N = 2851) was divided into 4 groups based on the index MDE duration at study entry: acute (≤ 6 months, N = 1324), subchronic (7-23 months, N = 807), chronic (24-41 months, N = 326), and ultrachronic (≥ 42 months, N = 394). These 4 groups were compared in terms of baseline sociodemographic and clinical characteristics and treatment outcomes. Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6. Logistic regression models with adjusted post hoc analyses were used to control for associated baseline characteristics. Response was defined as ≥ 50% reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDSSR-16) scores at exit. Remission was defined as ≤ 7 on the HAM-D-17 or ≤ 5 on the QIDS-SR-16. Results: MDE duration was longer in primary care settings, blacks, Hispanics, single or widowed, unemployed, publicly insured or uninsured, older, and less educated participants and in those with lower income, less recurrence, or greater concurrent general medical or Axis I comorbidities. HAM-D-17 remission rates ranged from 31.0% (acute group) to 24.1% (ultrachronic group). HAM-D-17 remission rates were significantly related to MDE duration (p = .0010), but after adjustments for baseline differences among the 4 groups, remission rates were not different. QIDS-SR-16 response rates were lower for the subacute and chronic groups but not different for the acute and ultrachronic groups after adjustment. Conclusion: Longer MDE duration is associated with socioeconomic disadvantage and greater Axis I and medical comorbidity. Episode duration per se does not significantly affect the likelihood of remission. Trial Registration: clinicaltrials.gov Identifier: NCT00021528.

AB - Objective: This article aims to identify baseline sociodemographic and clinical characteristics associated with the duration of the index major depressive episode (MDE) and to assess the effect of the current MDE duration on response and remission rates with up to 14 weeks of citalopram. Method: Eligible participants met DSM-IV criteria for nonpsychotic major depressive disorder, scored ≥ 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17), and were not resistant to adequate antidepressant treatment in the current episode. The first patient was enrolled in July 2001 and the last visit for the last patient in follow-up was in March 2006. The evaluable sample (N = 2851) was divided into 4 groups based on the index MDE duration at study entry: acute (≤ 6 months, N = 1324), subchronic (7-23 months, N = 807), chronic (24-41 months, N = 326), and ultrachronic (≥ 42 months, N = 394). These 4 groups were compared in terms of baseline sociodemographic and clinical characteristics and treatment outcomes. Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6. Logistic regression models with adjusted post hoc analyses were used to control for associated baseline characteristics. Response was defined as ≥ 50% reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDSSR-16) scores at exit. Remission was defined as ≤ 7 on the HAM-D-17 or ≤ 5 on the QIDS-SR-16. Results: MDE duration was longer in primary care settings, blacks, Hispanics, single or widowed, unemployed, publicly insured or uninsured, older, and less educated participants and in those with lower income, less recurrence, or greater concurrent general medical or Axis I comorbidities. HAM-D-17 remission rates ranged from 31.0% (acute group) to 24.1% (ultrachronic group). HAM-D-17 remission rates were significantly related to MDE duration (p = .0010), but after adjustments for baseline differences among the 4 groups, remission rates were not different. QIDS-SR-16 response rates were lower for the subacute and chronic groups but not different for the acute and ultrachronic groups after adjustment. Conclusion: Longer MDE duration is associated with socioeconomic disadvantage and greater Axis I and medical comorbidity. Episode duration per se does not significantly affect the likelihood of remission. Trial Registration: clinicaltrials.gov Identifier: NCT00021528.

UR - http://www.scopus.com/inward/record.url?scp=49649120470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649120470&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 1246

EP - 1256

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -